Try this starting point: what change are you hoping for? Write it in your own words. Bring that sentence to the visit, even if it feels hard to say.
Put the goal and medicine in writing
The US-approved use recorded on September 28, 2026, is excess belly fat linked to lipodystrophy in adults with HIV.
Lipodystrophy means a change in the body’s pattern of fat.
The label does not describe tesamorelin as a weight-loss treatment.
Ask the doctor to explain where your goal fits. A clear answer starts with your concern, rather than with a product name.
Name the medicine, then the plan
Tesamorelin (EGRIFTA SV, EGRIFTA WR) appears in different forms that the label says cannot be swapped for each other.
Request a written record of the product’s complete name. Then ask who will review tests, answer questions and decide whether the plan is helping.
Keep a place for the price
Ask for a written estimate that separates visits, tests and medicine. Leave room beside it for questions. An answer you cannot explain back in plain words needs another pass.
Read the source notes
Source-check dates: September 28, 2026.
Ask for confirmation of the current product, rules and costs before deciding on care.